ENGOT-OV42 / NSGO-AVATAR: A Three-arm Randomized Study to Evaluate the Efficacy of Niraparib-bevacizumab-dostarlimab Triplet Combination Against Niraparib-bevacizumab Doublet Combination and Against Standard of Care Therapy in Women With Relapsed Ovarian Cancer Where Platinum Combination Therapy is an Option.
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Bevacizumab (Primary) ; Dostarlimab (Primary) ; Niraparib (Primary) ; Carboplatin; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms ENGOT-OV42-NSGO/AVANOVA-Triplet
Most Recent Events
- 09 Jul 2021 Planned End Date changed from 1 Jun 2024 to 1 Dec 2024.
- 09 Jul 2021 Planned primary completion date changed from 1 Jun 2022 to 1 Dec 2022.
- 09 Jul 2021 Planned initiation date changed from 1 Jun 2019 to 1 Dec 2019.